Investigating how inhibiting PRMT5 affects cancers lacking the MTAP enzyme
Regulatory Pathways Compromised by PRMT5 Inhibition in Cancers with MTAP Loss
This study is looking at how a specific enzyme called PRMT5 affects certain cancers that don't have another enzyme called MTAP, which happens in about 15% of cancers, including tough ones like glioblastoma and pancreatic cancer, to find new ways to treat patients with these types of tumors.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11023817 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the PRMT5 enzyme in cancers that have lost the MTAP enzyme, which occurs in about 15% of all cancers, including aggressive types like glioblastoma and pancreatic cancer. The study uses advanced CRISPR technology to identify genes that influence how cancer cells respond to PRMT5 inhibition. By exploring these genetic interactions, the research aims to uncover new therapeutic targets and improve treatment strategies for patients with MTAP-deleted tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that have lost the MTAP enzyme, such as glioblastoma, pancreatic ductal adenocarcinoma, and esophageal cancer.
Not a fit: Patients whose cancers do not involve MTAP loss or those with other types of malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with specific types of cancer that currently have limited options.
How similar studies have performed: Other research has shown promising results with similar approaches targeting PRMT5 in MTAP-deleted cancers, indicating a potential for success in this area.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Wilson, Frederick H — Yale University
- Study coordinator: Wilson, Frederick H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.